Evaluating WAL0921 for kidney diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is an adaptive, multi-center, randomized, double-blind, placebo-controlled study aimed at assessing the safety and efficacy of WAL0921 in patients with various glomerular kidney diseases, including diabetic nephropathy and rare conditions like focal segmental glomerulosclerosis. Participants will receive either the investigational drug or a placebo via intravenous infusion every two weeks for a total of seven infusions. The study will monitor participants for 24 weeks following their last infusion to evaluate the drug's pharmacokinetics and pharmacodynamics.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults, age 18-75 years
* Diagnosis of one of the following glomerular kidney diseases: diabetic nephropathy; primary focal segmental glomerulosclerosis; treatment resistant-minimal change disease; primary IgA nephropathy; primary membranous nephropathy
* eGFR greater than or equal to 30 mL/min/1.73 m2

Exclusion Criteria:

* Currently pregnant or planning to become pregnant
* History of organ transplantation
* History of alcohol or substance use disorder
* Acute dialysis or acute kidney injury within 6 months of Screening
* Any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all study requirements

Where it's running

• Academic Medical Research Institute
  Los Angeles, California, United States Recruiting
• Colorado Kidney and Vascular Care
  Denver, Colorado, United States Recruiting
• D & H Tamarac Research Center
  Tamarac, Florida, United States Recruiting
• Fides Clinical Research
  Atlanta, Georgia, United States Recruiting
• Nephrology Associates of Northern Illinois and Indiana (NANI)
  Hinsdale, Illinois, United States Recruiting
• Dunes Clinical Research
  Dakota Dunes, South Dakota, United States Recruiting

Study contacts

• Study coordinator: Michelle Skupien
• Email: clinicaltrials@waldenbiosciences.com
• Phone: 8573141961

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Surovatamig for adults with anti‑PLA2R primary membranous nephropathy

  This study will test whether subcutaneous surovatamig is safe and can reduce heavy proteinuria in adults with anti‑PLA2R–positive primary membranous nephropathy.

  Recruiting Phase 2 AstraZeneca · Los Angeles, California and 26 other locations · NCT07571746

• Transformative 2.0 for diabetic kidney disease

  This project will try to see if adults with diabetic kidney disease who take SGLT2 diabetes medicines have different biological patterns in archived kidney tissue than similar people who do not take these medicines.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07444203

• SHR-2173 injections for adults with primary membranous nephropathy

  This Phase II test will try SHR-2173 injections in adults (18–75) with biopsy-proven primary membranous nephropathy to see if they are safe, reduce disease activity, and to measure how the drug acts in the body.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Nanjing, Jiangsu · NCT07289763

• Povetacicept for people with primary membranous nephropathy

  This trial tests whether povetacicept is safe and helps people with primary membranous nephropathy, with tacrolimus listed as an intervention in the protocol.

  Recruiting at 116 sites Phase 2/3 Vertex Pharmaceuticals Incorporated · Montgomery, Alabama and 116 other locations · NCT07204275

• ACE Reno Pico Cell Matrix for reducing proteinuria and supporting kidney function

  This trial will test whether taking ACE Reno, a sublingual peptide solution four times daily for 12 weeks, can lower urine protein and help stabilize kidney function in adults with nephropathy or chronic kidney disease.

  Recruiting Phase 4 Ace Cells Lab Limited · Giza, GZ · NCT07187713

• ALXN1920 for adults with primary membranous nephropathy

  This trial will test whether ALXN1920 reduces urine protein in adults with primary membranous nephropathy who are at high risk of progression compared with placebo.

  Recruiting at 35 sites Phase 2 Alexion Pharmaceuticals, Inc. · Loma Linda, California and 39 other locations · NCT07157787

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.